159 related articles for article (PubMed ID: 31068210)
1. A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats.
Lopes NL; Campos DR; Machado MA; Alves MSR; de Souza MSG; da Veiga CCP; Merlo A; Scott FB; Fernandes JI
BMC Vet Res; 2019 May; 15(1):137. PubMed ID: 31068210
[TBL] [Abstract][Full Text] [Related]
2. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats.
Ortalda C; Noli C; Colombo S; Borio S
Vet Dermatol; 2015 Aug; 26(4):235-e52. PubMed ID: 25940959
[TBL] [Abstract][Full Text] [Related]
3. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis.
Noli C; Matricoti I; Schievano C
Vet Dermatol; 2019 Apr; 30(2):110-e30. PubMed ID: 30656750
[TBL] [Abstract][Full Text] [Related]
4. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
Little PR; King VL; Davis KR; Cosgrove SB; Stegemann MR
Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.
Cosgrove SB; Wren JA; Cleaver DM; Martin DD; Walsh KF; Harfst JA; Follis SL; King VL; Boucher JF; Stegemann MR
Vet Dermatol; 2013 Oct; 24(5):479-e114. PubMed ID: 23829933
[TBL] [Abstract][Full Text] [Related]
6. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
Cosgrove SB; Wren JA; Cleaver DM; Walsh KF; Follis SI; King VI; Tena JK; Stegemann MR
Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
Carrasco I; Ferrer L; Puigdemont A
J Feline Med Surg; 2022 Aug; 24(8):787-793. PubMed ID: 34612749
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib.
Fukuyama T; Ganchingco JR; Bäumer W
Eur J Pharmacol; 2017 Jan; 794():20-26. PubMed ID: 27847179
[TBL] [Abstract][Full Text] [Related]
9. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
Cosgrove SB; Cleaver DM; King VL; Gilmer AR; Daniels AE; Wren JA; Stegemann MR
Vet Dermatol; 2015 Jun; 26(3):171-9, e35. PubMed ID: 25688708
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.
Gadeyne C; Little P; King VL; Edwards N; Davis K; Stegemann MR
Vet Dermatol; 2014 Dec; 25(6):512-8, e86. PubMed ID: 25109820
[TBL] [Abstract][Full Text] [Related]
11. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
Simpson AC; Schissler JR; Rosychuk RAW; Moore AR
Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca.
de Oliveira JK; Williams DL; Bollmann C; de Seabra NM; Bortolini M; Montiani-Ferreira F
Vet Ophthalmol; 2019 Sep; 22(5):633-643. PubMed ID: 30724448
[TBL] [Abstract][Full Text] [Related]
13. Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.
Panteri A; Strehlau G; Helbig R; Prost C; Doucette K
Vet Dermatol; 2016 Feb; 27(1):22-e7. PubMed ID: 26660461
[TBL] [Abstract][Full Text] [Related]
14. Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus.
Fleck T; Norris L; King V; Lesman S; Gonzales AJ
J Vet Pharmacol Ther; 2022 Jul; 45(4):380-384. PubMed ID: 35586953
[TBL] [Abstract][Full Text] [Related]
15. Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.
Barrett LE; Gardner HL; Barber LG; Sadowski A; London CA
BMC Vet Res; 2019 Aug; 15(1):291. PubMed ID: 31409327
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog.
Collard WT; Hummel BD; Fielder AF; King VL; Boucher JF; Mullins MA; Malpas PB; Stegemann MR
J Vet Pharmacol Ther; 2014 Jun; 37(3):279-85. PubMed ID: 24330031
[TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic study of oclacitinib maleate in six cats.
Ferrer L; Carrasco I; Cristòfol C; Puigdemont A
Vet Dermatol; 2020 Apr; 31(2):134-137. PubMed ID: 31769185
[TBL] [Abstract][Full Text] [Related]
18. Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis.
Gonzales AJ; Aleo M; Mahabir S; Messamore J; Stegemann M
J Vet Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38926932
[TBL] [Abstract][Full Text] [Related]
19. Use of oclacitinib as antipruritic drug during sarcoptic mange infestation treatment.
Cornegliani L; Guidi E; Vercelli A
Vet Dermatol; 2020 Dec; 31(6):505. PubMed ID: 33226173
[TBL] [Abstract][Full Text] [Related]
20. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs.
Marsella R; Ahrens K
Vet Dermatol; 2018 Oct; 29(5):439-e146. PubMed ID: 29926994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
